Literature DB >> 45131

Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites.

B M Cohen, M Herschel, A Aoba.   

Abstract

Chlorpromazine and thioridazine are widely used antipsychotic agents that are extensively metabolized. Parent compounds and metabolites have diverse pharmacologic activities, and differences in patterns of metabolism may explain differences in therapeutic and side effects from individual to individual. Radioreceptor assays were used to determine the neuroleptic, antimuscarinic, and anti-alpha-noradrenergic potency of chlorpromazine, thioridazine, and their metabolites. The results indicate that these metabolites show a wide range of potencies. The spectrum of activity of a metabolite may be quite different from that of its parent compound. The clinical relevance of these findings to individual differences in drug response is discussed. The combined use of radioreceptor assays and chemical assays in future clinical research is proposed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 45131     DOI: 10.1016/0165-1781(79)90062-3

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

1.  Fluphenazine activity and antipsychotic response.

Authors:  R J Hitzemann; D L Garver; M Mavroidis; J Hirschowitz; F P Zemlan
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Relationship between plasma concentration and arousal in normal subjects after single oral and parenteral doses of melperone, a butyrophenone neuroleptic.

Authors:  L Molander; L Borgström
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

3.  Serum neuroleptic concentrations and tardive dyskinesia.

Authors:  D V Jeste; M Linnoila; R L Wagner; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  Neuroleptic blood levels and therapeutic effect.

Authors:  B M Cohen; J F Lipinski; H G Pope; P Q Harris; R I Altesman
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate.

Authors:  B Szukalski; B Lipska; L Welbel; K Nurowska
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs.

Authors:  Bruce M Cohen; Sara Cherkerzian; Jianyi Ma; Nancy Ye; Carrie Wager; Nicholas Lange
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

7.  Structural basis of arc binding to synaptic proteins: implications for cognitive disease.

Authors:  Wenchi Zhang; Jing Wu; Matthew D Ward; Sunggu Yang; Yang-An Chuang; Meifang Xiao; Ruojing Li; Daniel J Leahy; Paul F Worley
Journal:  Neuron       Date:  2015-04-09       Impact factor: 17.173

8.  Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.

Authors:  G Bagdy; A Perényi; E Frecska; K Révai; Z Papp; M I Fekete; M Arató
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment.

Authors:  T Nakahara; M Hirano; H Uchimura; M Saito; J S Kim; T Matsumoto; H Yokoo; M Shimomura; A Mukai
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Sedative effects and prolactin response to single oral doses of melperone.

Authors:  L Molander; L Borgström
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.